Ardabelle Reveals a €7 Trillion Challenge for Europe: Invest Now or Lose a Generation of Competitiveness
7.4.2026 08:30:00 EEST | Business Wire | Press release
Europe is navigating a period of intense turbulence, where geopolitical crises, pressure on critical raw materials, and climate‑related shocks are reinforcing one another. This polycrisis is no longer cyclical: it is structurally reshaping the continent’s value chains and testing its industrial competitiveness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406787383/en/
Europe's Choice: €27T Coordinated Growth or €20T Fragmented Decline by 2050
In this context, Ardabelle is releasing Greening the Arteries of Industry, a groundbreaking study that quantifies for the first time the economic gap between a Europe that endures and a Europe that invests. Conducted under the scientific supervision of economist Xavier Jaravel, this work represents the first attempt to model, in an integrated way, industrial resilience, ecological transition, and European competitiveness through 2035 - 2050.
The study was presented under the high patronage of Roland Lescure, Minister for the Economy, Finance and Industrial, Energy and Digital Sovereignty, and Agnès Pannier‑Runacher, Minister for Ecological Transition and Territorial Cohesion, reflecting the strategic importance of these issues for France and for Europe.
The conclusion is unequivocal: a €7 trillion differential by 2050, nearly twice the current GDP of Germany.
The study shows that the inaction scenario - with GDP stagnating at €20 trillion in 2050 - exposes the continent to compounding climate damages, supply chain disruptions, and strategic dependencies. By contrast, a coordinated trajectory of green transition and industrial resilience would lift GDP to €27 trillion, driven by innovation, energy security, and the reconfiguration of supply chains.
Investing 2% of GDP per year between 2025 and 2030 would be enough to trigger this trajectory, with a 218% return on investment. Every euro invested generates €3.18 in benefits, including €2.50 from avoided climate damages alone.
Ardabelle: an architect of Europe’s value chains
Ardabelle positions itself as one of the few investment funds capable of combining macroeconomic analysis, micro‑level value chain expertise, financial acumen, and operational experience. This integrated approach enables the firm to support Europe’s SMEs and mid‑caps - 99% of European companies - as they transition toward more resilient, circular, and competitive business models.
Virginie Morgon, co-founder of Ardabelle declares: “This is not an ideological debate, but a battle for resilience and competitiveness. Europe’s value chains must be fundamentally rethought, and it is SMEs and mid-cap companies that hold the keys. Ardabelle is betting on a Europe that rebuilds, accelerates, and regains control of its industrial destiny.”
Eric Hazan, co‑founder of Ardabelle, states: “Europe is facing a €7 trillion bet. This is not a slogan - it is an economic choice. We are at a decisive moment for Europe’s industrial sovereignty. Either we invest now to build resilient value chains, or we accept structural decline. At Ardabelle, we believe resilience has become the new competitiveness - and we intend to be its architects.”
The full study is available here: https://ardabelle.com/articles/greening-arteries
About Ardabelle
Ardabelle Capital is a pioneering private equity firm focused on accelerating the transition to a sustainable, resilient economy. The firm is led by a world-class team of partners who bring together a rare blend of expertise from private equity, industry, and sustainability, combining decades of experience in transforming businesses and driving value across global markets. Ardabelle targets mid-market industrial, services, and technology businesses poised for international growth. With a unique value chain-driven strategy and a strong ecosystem of corporate partners, industry experts, and sustainability strategists, Ardabelle invests to drive long-term sustainable value.
For more information, visit ardabelle.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260406787383/en/
Contacts
Shahan Sheikholeslami - Ops Conseil
shahan@ops-conseil.com / +33 6 26 28 62 79
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom